Literature DB >> 27540431

Brain (18)F-FDG, (18)F-Florbetaben PET/CT, (123)I-FP-CIT SPECT and Cardiac (123)I-MIBG Imaging for Diagnosis of a "Cerebral Type" of Lewy Body Disease.

Axel Van Der Gucht1, Laurent Cleret de Langavant2, Ophélie Bélissant1, Corentin Rabu1, Anne-Ségolène Cottereau1, Eva Evangelista1, Julia Chalaye1, Sophie Bonnot-Lours1, Gilles Fénelon1, Emmanuel Itti1.   

Abstract

A 67-year-old man was referred for fluctuating neuropsychiatric symptoms, featuring depression, delirious episodes, recurrent visual hallucinations and catatonic syndrome associated with cognitive decline. No parkinsonism was found clinically even under neuroleptic treatment. (18)F-FDG PET/CT showed hypometabolism in the posterior associative cortex including the occipital cortex, suggesting Lewy body dementia, but (123)I-FP-CIT SPECT was normal and cardiac (123)I-MIBG imaging showed no signs of sympathetic denervation. Alzheimer's disease was excluded by a normal (18)F-florbetaben PET/CT. This report suggests a rare case of α-synucleinopathy without brainstem involvement, referred to as "cerebral type" of Lewy body disease.

Entities:  

Keywords:  (MeSH terms); 123I-FP-CIT; 18F-FDG; 18F-florbetaben; Brain imaging; Lewy body disease; MIBG

Year:  2016        PMID: 27540431      PMCID: PMC4977251          DOI: 10.1007/s13139-016-0394-0

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  8 in total

Review 1.  An introduction to PET and SPECT neuroreceptor quantification models.

Authors:  M Ichise; J H Meyer; Y Yonekura
Journal:  J Nucl Med       Date:  2001-05       Impact factor: 10.057

2.  Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older.

Authors:  T Rahkonen; U Eloniemi-Sulkava; S Rissanen; A Vatanen; P Viramo; R Sulkava
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-06       Impact factor: 10.154

3.  Fully automatic differential diagnosis system for dementia with Lewy bodies and Alzheimer's disease using FDG-PET and 3D-SSP.

Authors:  Atsushi K Kono; Kazunari Ishii; Keitaro Sofue; Naokazu Miyamoto; Setsu Sakamoto; Etsuro Mori
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02-22       Impact factor: 9.236

4.  Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias.

Authors:  Sean J Colloby; Shane McParland; John T O'Brien; Johannes Attems
Journal:  Brain       Date:  2012-09       Impact factor: 13.501

5.  The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies.

Authors:  Seok Ming Lim; Andrew Katsifis; Victor L Villemagne; Rene Best; Gareth Jones; Michael Saling; Jennifer Bradshaw; John Merory; Michael Woodward; Malcolm Hopwood; Christopher C Rowe
Journal:  J Nucl Med       Date:  2009-09-16       Impact factor: 10.057

6.  Validation of a standardized normalization template for statistical parametric mapping analysis of 123I-FP-CIT images.

Authors:  Aurélie Kas; Pierre Payoux; Marie-Odile Habert; Zoulikha Malek; Yann Cointepas; Georges El Fakhri; Philippe Chaumet-Riffaud; Emmanuel Itti; Philippe Remy
Journal:  J Nucl Med       Date:  2007-08-17       Impact factor: 10.057

7.  Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy.

Authors:  Zuzana Walker; Evelyn Jaros; Rodney W H Walker; Lean Lee; Durval C Costa; Gill Livingston; Paul G Ince; Robert Perry; Ian McKeith; Cornelius L E Katona
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03-12       Impact factor: 10.154

Review 8.  Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.

Authors:  I G McKeith; D W Dickson; J Lowe; M Emre; J T O'Brien; H Feldman; J Cummings; J E Duda; C Lippa; E K Perry; D Aarsland; H Arai; C G Ballard; B Boeve; D J Burn; D Costa; T Del Ser; B Dubois; D Galasko; S Gauthier; C G Goetz; E Gomez-Tortosa; G Halliday; L A Hansen; J Hardy; T Iwatsubo; R N Kalaria; D Kaufer; R A Kenny; A Korczyn; K Kosaka; V M Y Lee; A Lees; I Litvan; E Londos; O L Lopez; S Minoshima; Y Mizuno; J A Molina; E B Mukaetova-Ladinska; F Pasquier; R H Perry; J B Schulz; J Q Trojanowski; M Yamada
Journal:  Neurology       Date:  2005-10-19       Impact factor: 9.910

  8 in total
  1 in total

1.  Clinical impact of dual-tracer FDOPA and FDG PET/CT for the evaluation of patients with parkinsonian syndromes.

Authors:  Berivan Emsen; Gabriel Villafane; Jean-Philippe David; Eva Evangelista; Julia Chalaye; Lionel Lerman; François-Jérôme Authier; Jean-Michel Gracies; Emmanuel Itti
Journal:  Medicine (Baltimore)       Date:  2020-11-06       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.